Tagged with Merck,

Europe Ahead of the much-discussed implementation of an EU-wide legislative framework on joint clinical assessments in 2025, Merck’s Nikola Vesic outlines the scope and aims of the reform and highlights some of the challenges in bridging the gap between theoretical vision and practical implementation.*     In 2022, the European Union…

Greece Greece is a middling performer in terms of clinical trial numbers on the European stage, nestled next to Finland and Romania on total trial numbers between 2002 and 2020 but ahead of Germany and Italy on trials per capita. However, the pharmaceutical industry does see opportunities for establishing greater trial…

Greece Merck Greece’s Susan King-Barnardo outlines how she navigated the affiliate through the challenging waters of COVID-19, the unique market access challenges that innovative pharma is facing in Greece, Merck’s burgeoning clinical trial footprint in the country, and her approach to fostering diversity, equity, and inclusion.   There is a lot…

Global At the recent World Economic Forum in Davos, Chair of the Executive Board and CEO of Merck, Belén Garijo, speaking in a session on workforce transformation in the digital era, shared lessons from the COVID-19 pandemic experience, insights into the importance of building leadership skills, and using technology as an…

Germany The latest from German pharma, including Merck KGaA’s increased gamble on external innovation, Bayer’s focus supply chain stability, CatalYm’s EUR 50 million series C financing and Boehringer Ingelheim’s deal with California biotech, Surrozen.   German CDMO Rentschler’s chief executive, Frank Mathias, stepping down (Fierce Pharma) After seven years at the…

Global The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this year’s edition that the 20 companies surveyed have firmly responded to access issues exposed by COVID-19. GSK remains at the…

Singapore MSD is set to inject an additional USD 500 million into its existing Singapore manufacturing operations with two new facilities to produce vaccines and biologics. One of the new plants will turn out MSD’s immunotherapy for cancer and its human papillomavirus (HPV) vaccine for the Asia-Pacific region. The reason we…

Global Fortune’s new 50 Most Powerful Women in Business list features four representatives of Big Pharma, as well as a further four from powerful US health insurance corporations.   The annual ranking is based on five criteria: the size and importance of a leader’s business in the global economy, the health…

Germany A roundup of some of the biggest recent stories from German pharma, including the latest on beleaguered Bayer CEO Werner Baumann, Merck KGaA’s latest investments in France and Germany, and STADA securing the first authorized treatment in Europe for the rare kidney disease immunoglobulin A nephropathy (IgAN).   Bayer’s hunt…

Global Merck has agreed to front USD 150 million for Orna Therapeutics’ new investigational class of engineered circular RNA (oRNA) therapies in a collaboration agreement that will also provide the biotech series B financing. This broad strategic collaboration brings together Merck’s significant expertise … with Orna’s compelling circular RNA technology to…

Global Merck Group’s Vice President Global Market Access & Pricing Strategic Planning, Marco Rauland, takes a look at recent advancements in Machine Learning and Artificial Intelligence and how these technologies can offer a sophisticated and flexible approach not only to predicting drug pricing, but also to estimating market access with different…

Italy Italy, Europe’s fourth largest pharma market at a size of EUR 23.446 billion, has a highly decentralised healthcare system, with the country’s 20 regions negotiating market access for medicines individually following central regulatory approval. This creates significant complexities for the representatives of Big Pharma looking to roll out their latest…